Gene
PAK1
PAK1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (1), Target-disease associations (159), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention PAK1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 2 of 11,460 | 0.02% |
| 2022 | 7 of 13,598 | 0.05% |
| 2021 | 7 of 15,045 | 0.05% |
| 2020 | 8 of 14,459 | 0.06% |
| 2019 | 4 of 12,159 | 0.03% |
| 2018 | 9 of 11,854 | 0.08% |
| 2017 | 7 of 11,595 | 0.06% |
| 2016 | 7 of 10,983 | 0.06% |
| 2015 | 3 of 11,395 | 0.03% |
| 2014 | 3 of 10,367 | 0.03% |
Showing 10 of 34 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Gencurix Inc. | Diagnostic provider | Clinical validationAnalytical validation | 1 | December 01, 2026 (scheduled journal issue - may already be available ahead of print) |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PAK1 amplification | Pak Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
Target-disease associations (159)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Autoimmune Hepatitis | endocrine system disease | Literature (Europe PMC) |
| COVID-19 | infectious disease | Literature (Europe PMC) |
| Combined hyperlipidemia | endocrine system disease | Mouse knockout (IMPC) |
| Cutaneous T-cell lymphoma | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 159 associations.
Vendor sourcing (12)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense changes are a common disease-causing mechanism. Damaging e... | View ClinVar record SCV005905671.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1225G>A (p.G409R) alteration is located in exon 13 (coding exon 12) of the PAK1 gene. This alteration results from a G to A substitution at nucleotide ... | View ClinVar record SCV001444600.4 |
| Centre Hospitalier Universitaire de Nantes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV004101239.1 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_002576.5(PAK1):c.190+5A>G is a splice-region variant predicted to affect normal RNA splicing. This variant is rare in population databases. The currently ... | View ClinVar record SCV007659794.2 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein str... | View ClinVar record SCV001788402.2 |
Showing 5 of 12 sourcing records.
Trial-cited literature (71)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Clinical and functional spectrum of RAC2-related immunodeficiency. | Blood | 2024 | 23 |
| RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation. | The Journal of experimental medicine | 2024 | 9 |
| Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. | Nature communications | 2023 | 47 |
| Probing the diabetes and colorectal cancer relationship using gene - environment interaction analyses. | British journal of cancer | 2023 | 11 |
| Mechanisms of podocyte injury and implications for diabetic nephropathy. | Clinical science (London, England : 1979) | 2022 | 185 |
Showing 5 of 71 papers.
Protein variant mentions (5)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.I476T | 1 | 2015 | PMID 25741868 |
| p.R272W | 1 | 2015 | PMID 25741868 |
| p.R495G | 1 | 2015 | PMID 25741868 |
| p.Y131C | 1 | 2015 | PMID 25741868 |
| p.Y429C | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (16)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Propolis | Chemical | negative_correlate |
Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. | 2020 |
| Hydroxychloroquine | Chemical | negative_correlate |
PAK1-blockers: Potential Therapeutics against COVID-19. | 2020 |
| Ketorolac | Chemical | negative_correlate |
PAK1-blockers: Potential Therapeutics against COVID-19. | 2020 |
| MELATONIN | Chemical | negative_correlate |
PAK1-blockers: Potential Therapeutics against COVID-19. | 2020 |
| Propolis | Chemical | negative_correlate |
PAK1-blockers: Potential Therapeutics against COVID-19. | 2020 |
Showing 5 of 16 relation assertions.
Organizations publishing (126)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 5 | 2018 to 2024 |
| Harris Health System | Hospital | 4 | 2011 to 2018 |
| University of Oxford | Academic | 4 | 2011 to 2018 |
| Mass General Brigham | Hospital | 3 | 2016 to 2024 |
| University of Zurich | Academic | 3 | 2014 to 2020 |
Showing 5 of 126 organizations.
Where PAK1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
150 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, trial mentions, and human sample screening reference.